Joel Lewis's most recent trade in Galectin Therapeutics Inc was a trade of 84,000 Restricted Stock Unit done . Disclosure was reported to the exchange on Jan. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 84,000 | 0 | - | - | Restricted Stock Unit | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 84,000 | 916,592 (1%) | 0% | 0 | Common Stock | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.58 per share. | 02 Jan 2026 | 37,698 | 832,592 (1%) | 0% | 3.6 | 134,853 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.91 per share. | 02 Jan 2026 | 27,731 | 870,290 (1%) | 0% | 3.9 | 108,342 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.20 per share. | 02 Jan 2026 | 18,571 | 898,021 (1%) | 0% | 4.2 | 77,939 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.86 per share. | 17 Dec 2025 | 7,829 | 840,421 (1%) | 0% | 2.9 | 22,391 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2025 | 7,829 | 32,171 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.06 per share. | 17 Dec 2025 | 7,829 | 832,592 (1%) | 0% | 7.1 | 55,241 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 6.04 per share. | 17 Nov 2025 | 15,680 | 832,592 (1%) | 0% | 6.0 | 94,643 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 15,680 | 6,783 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 17 Nov 2025 | 15,680 | 848,272 (1%) | 0% | 2.4 | 37,475 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 6,783 | 0 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 6.15 per share. | 17 Nov 2025 | 6,783 | 832,592 (1%) | 0% | 6.2 | 41,723 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 17 Nov 2025 | 6,783 | 839,375 (1%) | 0% | 2.4 | 16,211 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 6.03 per share. | 10 Nov 2025 | 1,867 | 832,592 (1%) | 0% | 6.0 | 11,252 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2025 | 1,867 | 22,363 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 10 Nov 2025 | 1,867 | 834,459 (1%) | 0% | 2.4 | 4,462 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2025 | 200 | 24,230 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 6.00 per share. | 05 Nov 2025 | 200 | 832,592 (1%) | 0% | 6 | 1,200 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 05 Nov 2025 | 200 | 832,792 (1%) | 0% | 2.4 | 478 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 14,420 | 24,530 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 03 Nov 2025 | 14,420 | 847,012 (1%) | 0% | 2.4 | 34,464 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 6.07 per share. | 03 Nov 2025 | 14,420 | 832,592 (1%) | 0% | 6.1 | 87,529 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 03 Nov 2025 | 1,300 | 833,892 (1%) | 0% | 2.4 | 3,107 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 6.01 per share. | 03 Nov 2025 | 1,300 | 832,592 (1%) | 0% | 6.0 | 7,813 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 1,300 | 38,950 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 12 Sep 2025 | 14,000 | 846,592 (1%) | 0% | 2.4 | 33,460 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 6.36 per share. | 12 Sep 2025 | 14,000 | 832,592 (1%) | 0% | 6.4 | 89,048 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2025 | 14,000 | 40,250 | - | - | Stock option (right to buy) | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.57 per share. | 03 Mar 2025 | 56,420 | 832,592 (1%) | 0% | 1.6 | 88,579 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 91,000 | 91,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 84,000 | 84,000 | - | - | Restricted Stock Unit | |
| Galectin Therapeutics Inc | Lewis Joel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 56,000 | 0 | - | - | Restricted Stock Units | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 56,000 | 953,012 (1%) | 0% | 0 | Common Stock | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.89 per share. | 23 Dec 2024 | 56,000 | 897,012 (1%) | 0% | 0.9 | 49,610 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 3.39 per share. | 24 Apr 2024 | 1,000 | 2,000 (0%) | 0% | 3.4 | 3,390 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.96 per share. | 01 Mar 2024 | 152,584 | 897,716 (1%) | 0% | 2.0 | 299,065 | Common Stock |
| Galectin Therapeutics Inc | Lewis Joel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 91,000 | 91,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 56,000 | 56,000 | - | - | Restricted Stock Unit | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.66 per share. | 29 Dec 2023 | 11,606 | 1,042,300 (1%) | 0% | 1.7 | 19,266 | Common Stock |
| Galectin Therapeutics Inc | Lewis Joel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.60 per share. | 15 Dec 2023 | 12,042 | 1,030,694 (1%) | 0% | 1.6 | 19,267 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.95 per share. | 30 Nov 2023 | 9,880 | 1,018,652 (1%) | 0% | 2.0 | 19,266 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.87 per share. | 15 Nov 2023 | 10,303 | 1,008,772 (1%) | 0% | 1.9 | 19,267 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.04 per share. | 31 Oct 2023 | 9,444 | 998,469 (1%) | 0% | 2.0 | 19,266 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.01 per share. | 13 Oct 2023 | 9,585 | 989,025 (1%) | 0% | 2.0 | 19,266 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.92 per share. | 29 Sep 2023 | 10,035 | 979,440 (1%) | 0% | 1.9 | 19,267 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.76 per share. | 15 Sep 2023 | 10,947 | 969,405 (1%) | 0% | 1.8 | 19,267 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.75 per share. | 31 Aug 2023 | 11,010 | 958,458 (1%) | 0% | 1.8 | 19,268 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.60 per share. | 15 Aug 2023 | 12,042 | 947,448 (1%) | 0% | 1.6 | 19,267 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.50 per share. | 31 Jul 2023 | 12,844 | 935,406 (1%) | 0% | 1.5 | 19,266 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.63 per share. | 14 Jul 2023 | 11,820 | 922,562 (1%) | 0% | 1.6 | 19,267 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.44 per share. | 30 Jun 2023 | 13,380 | 910 (0%) | 0% | 1.4 | 19,267 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.46 per share. | 15 Jun 2023 | 13,196 | 897,362 (1%) | 0% | 1.5 | 19,266 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.57 per share. | 31 May 2023 | 12,272 | 884,166 (1%) | 0% | 1.6 | 19,267 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.64 per share. | 15 May 2023 | 11,748 | 871,894 (1%) | 0% | 1.6 | 19,267 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.76 per share. | 28 Apr 2023 | 10,947 | 860,146 (1%) | 0% | 1.8 | 19,267 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.01 per share. | 14 Apr 2023 | 9,585 | 849,199 (1%) | 0% | 2.0 | 19,266 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.10 per share. | 31 Mar 2023 | 9,175 | 839,614 (1%) | 0% | 2.1 | 19,268 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.90 per share. | 15 Mar 2023 | 10,140 | 830,439 (1%) | 0% | 1.9 | 19,266 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.07 per share. | 28 Feb 2023 | 75,529 | 820,299 (1%) | 0% | 2.1 | 156,345 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.07 per share. | 28 Feb 2023 | 9,308 | 895,828 (1%) | 0% | 2.1 | 19,268 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 1.52 per share. | 16 Feb 2023 | 1,000 | 1,000 (0%) | 0% | 1.5 | 1,520 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.44 per share. | 15 Feb 2023 | 13,380 | 886,520 (1%) | 0% | 1.4 | 19,267 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.43 per share. | 07 Feb 2023 | 143,836 | 873,140 (1%) | 0% | 1.4 | 205,685 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.16 per share. | 31 Jan 2023 | 15,086 | 729,304 (1%) | 0% | 1.2 | 17,500 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.14 per share. | 13 Jan 2023 | 15,351 | 714,218 (1%) | 0% | 1.1 | 17,500 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.13 per share. | 30 Dec 2022 | 15,487 | 698,867 (1%) | 0% | 1.1 | 17,500 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.16 per share. | 15 Dec 2022 | 15,086 | 683,380 (1%) | 0% | 1.2 | 17,500 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.27 per share. | 30 Nov 2022 | 13,780 | 668,294 (1%) | 0% | 1.3 | 17,501 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.24 per share. | 15 Nov 2022 | 14,113 | 654,514 (1%) | 0% | 1.2 | 17,500 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.38 per share. | 31 Oct 2022 | 12,681 | 640,401 (1%) | 0% | 1.4 | 17,500 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.62 per share. | 14 Oct 2022 | 10,802 | 627,720 (1%) | 0% | 1.6 | 17,499 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.63 per share. | 30 Sep 2022 | 10,736 | 616,918 (1%) | 0% | 1.6 | 17,500 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.79 per share. | 15 Sep 2022 | 9,777 | 606,182 (1%) | 0% | 1.8 | 17,501 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.90 per share. | 31 Aug 2022 | 9,211 | 596,405 (1%) | 0% | 1.9 | 17,501 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.18 per share. | 15 Aug 2022 | 8,028 | 587,194 (1%) | 0% | 2.2 | 17,501 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.26 per share. | 29 Jul 2022 | 7,743 | 552,139 (0%) | 0% | 2.3 | 17,499 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.65 per share. | 15 Jul 2022 | 10,606 | 544,396 (0%) | 0% | 1.7 | 17,500 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.31 per share. | 30 Jun 2022 | 13,359 | 533,790 (0%) | 0% | 1.3 | 17,500 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.29 per share. | 15 Jun 2022 | 13,780 | 520,431 (0%) | 0% | 1.3 | 17,776 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.29 per share. | 31 May 2022 | 13,566 | 506,651 (0%) | 0% | 1.3 | 17,500 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.36 per share. | 13 May 2022 | 12,868 | 493,085 (0%) | 0% | 1.4 | 17,500 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.55 per share. | 29 Apr 2022 | 11,290 | 480,217 (0%) | 0% | 1.6 | 17,500 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.74 per share. | 15 Apr 2022 | 10,057 | 468,927 (0%) | 0% | 1.7 | 17,499 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.61 per share. | 31 Mar 2022 | 10,870 | 458,870 (0%) | 0% | 1.6 | 17,501 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.74 per share. | 15 Mar 2022 | 10,057 | 448,000 (0%) | 0% | 1.7 | 17,499 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.87 per share. | 28 Feb 2022 | 9,358 | 437 (0%) | 0% | 1.9 | 17,499 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.07 per share. | 15 Feb 2022 | 8,454 | 428,585 (0%) | 0% | 2.1 | 17,500 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.93 per share. | 31 Jan 2022 | 112,263 | 420,131 (0%) | 0% | 1.9 | 216,668 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.02 per share. | 14 Jan 2022 | 8,251 | 307,868 (0%) | 0% | 2.0 | 16,667 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.25 per share. | 15 Dec 2021 | 7,407 | 291,565 (0%) | 0% | 2.3 | 16,666 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.63 per share. | 30 Nov 2021 | 6,337 | 284,158 (0%) | 0% | 2.6 | 16,666 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.86 per share. | 15 Nov 2021 | 5,828 | 277,821 (0%) | 0% | 2.9 | 16,668 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.17 per share. | 29 Oct 2021 | 5,258 | 271,993 (0%) | 0% | 3.2 | 16,668 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.37 per share. | 15 Oct 2021 | 4,946 | 266,735 (0%) | 0% | 3.4 | 16,668 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.88 per share. | 30 Sep 2021 | 4,296 | 261,789 (0%) | 0% | 3.9 | 16,668 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.73 per share. | 15 Sep 2021 | 4,468 | 257,493 (0%) | 0% | 3.7 | 16,666 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.93 per share. | 31 Aug 2021 | 4,241 | 253,025 (0%) | 0% | 3.9 | 16,667 | Common Stock |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.38 per share. | 13 Aug 2021 | 4,931 | 248,784 (0%) | 0% | 3.4 | 16,667 | Common Stock |